Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218Angeles Alvarez Secord, Andrew B. Nixon, David M. O’Malley et al.|Clinical Cancer Research|2020Cited by 57
Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving RegorafenibYingmiao Liu, Andrew B. Nixon, Jing Lyu et al.|Molecular Cancer Therapeutics|2020Cited by 30
Blood‐based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from <scp>CALGB</scp> 80203 (Alliance)Ace J. Hatch, Andrew B. Nixon, Alexander B. Sibley et al.|Cancer Medicine|2016Cited by 20
Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or Bev plus Cetux: Results from CALGB 80405 (Alliance).Andrew B. Nixon, Herbert I. Hurwitz, Alexander B. Sibley et al.|Journal of Clinical Oncology|2016Cited by 15
Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF therapy.Yingmiao Liu, Andrew B. Nixon, Zhenhua Yuan et al.|Journal of Clinical Oncology|2017Cited by 1